Sigyn Therapeutics Files 8-K with Corporate Updates
Ticker: SIGY · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1642159
| Field | Detail |
|---|---|
| Company | Sigyn Therapeutics, Inc. (SIGY) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
TL;DR
Sigyn Therapeutics filed an 8-K on Dec 30, 2024, with corporate and financial updates.
AI Summary
Sigyn Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events as of December 30, 2024. The filing includes amendments to its articles of incorporation or bylaws and financial statements. The company, formerly known as Reign Resources Corp and Reign Sapphire Corp, is incorporated in Delaware and has a fiscal year end of December 31.
Why It Matters
This 8-K filing indicates corporate actions and financial reporting by Sigyn Therapeutics, Inc., providing transparency to investors about the company's structure and financial status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not inherently present new risks.
Key Numbers
- 000-55575 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-4210559 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Sigyn Therapeutics, Inc. (company) — Registrant
- Reign Resources Corp (company) — Former company name
- Reign Sapphire Corp (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- December 30, 2024 (date) — Date of earliest event reported
- January 6, 2025 (date) — Filing date
FAQ
What specific amendments were made to Sigyn Therapeutics' articles of incorporation or bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the excerpt.
What is the primary purpose of this 8-K filing?
The filing serves as a current report to disclose significant corporate events, including amendments to governing documents and financial statements, as of December 30, 2024.
When was Sigyn Therapeutics, Inc. previously known by other names?
The company was formerly known as Reign Resources Corp (name change date: 20200512) and Reign Sapphire Corp (name change date: 20150512).
What is Sigyn Therapeutics' fiscal year end?
The company's fiscal year ends on December 31.
Where is Sigyn Therapeutics, Inc. located?
The company's business and mailing address is 9190 W Olympic Blvd # 263, Beverly Hills, CA 90212.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-01-06 17:25:50
Key Financial Figures
- $0.0001 — Million (100,000,000) shares, par value $0.0001. Our authorized preferred stock stayed
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex3-1.htm (EX-3.1) — 14KB
- 0001493152-25-001074.txt ( ) — 224KB
- sigy-20241230.xsd (EX-101.SCH) — 3KB
- sigy-20241230_lab.xml (EX-101.LAB) — 33KB
- sigy-20241230_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 30, 2024, we filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation with the State of Delaware, which went effective immediately upon filing. The Certificate of Amendment decreased our authorized common stock to One Hundred Million (100,000,000) shares, par value $0.0001. Our authorized preferred stock stayed the same at Ten Million (10,000,000) shares, par value $0.0001. Section 9 – Financial Statements and Exhibits Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation filed December 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SIGYN THERAPEUTICS, INC. Date: January 6, 2025 By: /s/ James A. Joyce James A. Joyce, Chairman and CEO